Miralax

Constipation, Exophthalmos, Bowel preparation therapy + 8 more

Treatment

3 FDA approvals

20 Active Studies for Miralax

What is Miralax

Polyethylene glycol

The Generic name of this drug

Treatment Summary

Polyethylene glycol (PEG) is a synthetic polymer made from ethylene glycol molecules joined by an ether linkage. Depending on the molecular weight, PEGs can be liquids or waxy solids. The most common types are PEG 3350 and PEG 400. PEGs have different applications in medical and industrial fields. PEG 3350 is an over-the-counter osmotic laxative used to treat constipation, and PEG 3350 is also used to cleanse the colon before a colonoscopy. PEGs are useful in gastroenterology because they have strong water-binding capacity

GoLYTELY

is the brand name

image of different drug pills on a surface

Miralax Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

GoLYTELY

Polyethylene glycol

1984

207

Approved as Treatment by the FDA

Polyethylene glycol, also known as GoLYTELY, is approved by the FDA for 3 uses such as Constipation and Constipation .

Constipation

Constipation

Constipation

Effectiveness

How Miralax Affects Patients

PEG 3350 causes diarrhea by increasing the amount of water in the intestines. Effects usually start within 1-2 hours after taking it. When used to prepare for a colonoscopy, it is often combined with electrolytes to prevent dehydration. Over-the-counter versions of PEG 3350 do not contain any salts that can be absorbed. Studies have shown that it does not affect the ability of the intestines to absorb fluids or create and maintain electrochemical gradients.

How Miralax works in the body

Osmotic laxatives contain substances that draw water into the large intestine, making the stool softer and easier to pass. One such substance is polyethylene glycol, which binds to water molecules and causes them to accumulate in the colon. This accumulation leads to looser stools.

When to interrupt dosage

The recommended dosage of Miralax is contingent upon the diagnosed disorder, such as Dry Eye Syndrome, Bowel preparation therapy and Chronic Constipation. The quantity of dosage may deviate, depending on the method of delivery outlined in the table hereunder.

Condition

Dosage

Administration

Dry Eye Syndrome

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Constipation

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Colon Cleansing for Colonoscopy

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Constipation

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Exophthalmos

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Bowel preparation therapy

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Colonoscopy

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Dry Eye Syndrome

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Chronic Constipation

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Obesity

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Eye

, 1.7 mg/mg, 236.0 mg/mL, 17000.0 mg, 1700.0 mg/hour, 420.0 mg/mL, 17.0 mg/mg, 2.4 mg/mg, 4.2 mg/mg, 2.36 mg/mg, 227.1 mg/mL, 210.0 mg/mL, 1.0 mg/mg, 0.55 mg/mg, 100.0 %, 1.0 %, 15.0 %, 236000.0 mg, 59550.0 mg, 238180.0 mg, 14750.0 mg, 59000.0 mg, 240.0 mg/mL, 10.0 mg/mL, 150.0 mg/mL, 210000.0 mg, 0.15 mg/mg, 100.0 mg/mL, 40000.0 mg, 60.0 mg/mL, 100000.0 mg, 0.2 %, 140000.0 mg, 17000.0 mg/dose, 160.0 mg/mL, 0.152 mg/mg, 0.85769 mg/mg, 59.55 mg/mL, 2.388 mg/mg, 2.382 mg/mg

Oral, , Powder, for solution, Powder, for solution - Oral, Powder, Powder - Oral, Powder, for solution - Topical, Topical, Powder, for solution - Nasogastric; Oral, Nasogastric; Oral, Cream, Cream - Topical, Liquid, Liquid - Ophthalmic, Ophthalmic, Gel, Nasal, Kit; Powder, for solution; Tablet, delayed release, Kit; Powder, for solution; Tablet, delayed release - Oral, Spray, metered - Nasal, Gel - Nasal, Spray, Solution - Oral, Liquid - Oral, Powder - Topical, Nasogastric, Powder, for solution - Nasogastric, Kit, Kit - Oral, Aerosol, metered - Nasal, Aerosol, metered, Powder, for suspension - Oral, Solution - Ophthalmic, Spray - Nasal, Oral; Topical, Kit - Oral; Topical, Solution / drops, Solution / drops - Ophthalmic, Oral; Rectal, Solution, Spray, metered, Gel - Topical, Powder, for suspension

Warnings

Miralax Contraindications

Condition

Risk Level

Notes

Toxic colitis

Do Not Combine

Intestinal Perforation

Do Not Combine

Megacolon, Toxic

Do Not Combine

Gastric Retention

Do Not Combine

Gastrointestinal obstruction

Do Not Combine

Ileus

Do Not Combine

There are 20 known major drug interactions with Miralax.

Common Miralax Drug Interactions

Drug Name

Risk Level

Description

Bisacodyl

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Bisacodyl.

Bisoxatin

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Bisoxatin.

Dantron

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Dantron.

Deacetylbisacodyl

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Deacetylbisacodyl.

Oxyphenisatin

Major

The risk or severity of mucosal ulceration and ischemic colitis can be increased when Polyethylene glycol is combined with Oxyphenisatin.

Miralax Toxicity & Overdose Risk

The lowest toxic dose of PEG 3350 in rats has been found to be 22000 mg/kg. Too much PEG 3350 may cause diarrhea, and those who overdose should be given supportive treatments to help with their symptoms.

image of a doctor in a lab doing drug, clinical research

Miralax Novel Uses: Which Conditions Have a Clinical Trial Featuring Miralax?

67 active clinical trials are being conducted to determine the utility of Miralax in providing Bowel preparation therapy, Body weight >20kg and Exophthalmos relief.

Condition

Clinical Trials

Trial Phases

Exophthalmos

1 Actively Recruiting

Phase 1

Constipation

15 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3, Phase 1

Constipation

0 Actively Recruiting

Colon Cleansing for Colonoscopy

0 Actively Recruiting

Eye

0 Actively Recruiting

Chronic Constipation

2 Actively Recruiting

Phase 4, Not Applicable

Dry Eye Syndrome

14 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 2, Phase 3

Bowel preparation therapy

1 Actively Recruiting

Phase 1, Phase 2

Obesity

0 Actively Recruiting

Dry Eye Syndrome

12 Actively Recruiting

Phase 4, Phase 2, Not Applicable

Colonoscopy

4 Actively Recruiting

Not Applicable, Phase 1

Miralax Reviews: What are patients saying about Miralax?

5

Patient Review

8/14/2022

Miralax for Incomplete or Infrequent Bowel Movements

I've had chronic constipation since childhood and it's only gotten worse as I've aged. Miralax is a lifesaver that helps me avoid severe symptoms on a daily basis.

5

Patient Review

10/1/2022

Miralax for Incomplete or Infrequent Bowel Movements

I've had IBS for over 30 years, and this is the best treatment I've ever found. Thank you, Marilax!

5

Patient Review

12/13/2019

Miralax for Emptying of the Bowel

This medication helped me heal my fissure quickly and effectively.

4.7

Patient Review

9/4/2019

Miralax for Incomplete or Infrequent Bowel Movements

I've been trying different treatments for my constipation for many years now, and Miralax seems to be doing the best job. I'm using it daily in combination with magnesium citrate, and so far so good.

4

Patient Review

8/25/2021

Miralax for Incomplete or Infrequent Bowel Movements

I take this medication every day without any issues. It's very effective and I'm 74 years old.

4

Patient Review

2/4/2019

Miralax for Incomplete or Infrequent Bowel Movements

The product works well, but I have difficulty holding and measuring the dosage from the container.

3.7

Patient Review

12/30/2021

Miralax for Incomplete or Infrequent Bowel Movements

This medication does help, but I often feel nauseous after taking it.

2.7

Patient Review

8/18/2019

Miralax for Incomplete or Infrequent Bowel Movements

I experienced some very severe and unpleasant side effects after taking only one dose of this product. I ended up in the emergency room with cramping, dizziness, nausea, back pain, and more. Thankfully, the CT scan and blood tests came back normal. However, I will definitely be looking for a different constipation remedy in the future.

2.3

Patient Review

9/1/2018

Miralax for Incomplete or Infrequent Bowel Movements

I had some bad abdominal pains after taking this medication for a few days, as prescribed by my doctor. I'm going to look for something else because chronic constipation is an issue for me and I'm getting older.

1.7

Patient Review

7/31/2018

Miralax for Incomplete or Infrequent Bowel Movements

While this drug did help with my constipation issue, the back pain it caused was unbearable. I stopped taking it and will never go near it again.

1

Patient Review

4/18/2020

Miralax for Incomplete or Infrequent Bowel Movements

I experienced severe stomach pain and rectal bleeding after taking this drug. Additionally, I was incredibly dizzy and did not have a single bowel movement. I believe that a class action lawsuit should be filed against the company for their sale of this dangerous, untested drug.

1

Patient Review

11/9/2019

Miralax for Emptying of the Bowel

Unfortunately, this medication caused me a great deal of discomfort. I experienced hot flashes, cramps, and constipation. I stopped and started the medication three different times to be sure it was Miralax that was causing the problems, and it unfortunately was.

1

Patient Review

2/8/2022

Miralax for Emptying of the Bowel

I cannot recommend this medication. I began vomiting shortly after taking it as prescribed, and ended up having to cancel my colonoscopy because I couldn't keep the medicine down. This was a terrible experience all around.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about miralax

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is MiraLAX a stool softener or laxative?

"MiraLAX is a laxative that works by drawing water into the colon, which softens the stool and may stimulate the colon to contract. These actions help ease bowel movements. Colace is a stool softener."

Answered by AI

How long does it take for MiraLAX to make you poop?

"MiraLAX typically causes bowel movements to begin within an hour of consumption, but this may differ for some people. There is no need to be concerned if you do not have a bowel movement after drinking the first half of the MiraLAX, simply continue to drink liquids and consume the second half as directed."

Answered by AI

How much does MiraLAX make you poop?

"You can start taking MiraLAX when you first notice constipation, and continuing taking it once a day until you're relieved of constipation (up to 7 days maximum, or as directed by your doctor)."

Answered by AI

What does MiraLAX do to you?

"The purpose of this medication is to treat constipation that occurs occasionally. It does this by causing the stool to retain water which then softens the stool and increases the number of bowel movements. This medication is classified as an osmotic-type laxative."

Answered by AI

Clinical Trials for Miralax

Image of The Southern College of Optometry in Memphis, United States.

Acoltremon for Dry Eye

18+
All Sexes
Memphis, TN

The goal of this clinical trial is to \[primary purpose is to learn if accordingly, the purpose of this study is to evaluate the effects of acoltremon in participants with evaporative DED, with a focus on characterizing how symptoms and evaporative DED signs change over the first month of treatment. \[primary hypothesis or outcome measure 1\] Change in unanesthetized Schirmer test score between pre-drop at baseline compared to post-drop score on Day 1 Researchers will compare all of the enrolled participants, and everyone will be provided the same treatment. Participants will • 2. Eye Dryness VAS: A 0-100 Eye Dryness VAS will be completed by the participants. * 3\. OSDI: The OSDI (0-100) will be completed by the subjects. * 4\. Visual Acuity: The participant's current corrected visual acuity will be measured with a high-contrast, Snellen chart. If the participant is unable to read the 20/40 letters (0.3 logMAR), the investigator will pinhole over the participant's unaided or presenting refractive error correction to determine the participant's visual potential. * 5\. Slit-Lamp Biomicroscopy: The investigator will use a slit-lamp biomicroscope to document normal and/or remarkable findings of the anterior eye structures: eyelashes, eyelids, conjunctiva, and cornea. * Schirmer's Test without Anesthesia (Pre-Drop): Schirmer's I test will be performed on each eye for 5 minutes. The amount of wetting will be measured on each strip. * Drop Application: 15 minutes after the pre-drop Schirmer's Test, one drop of acoltremon 0.003% will be applied to each eye. * Schirmer's Test without Anesthesia (Post-Drop): Schirmer's I test will be performed on each eye for 5 minutes 3 minutes post-drop application. The amount of wetting will be measured on each strip. * Tear Break Up Time (TBUT): TBUT will be determined by instilling sodium fluorescein using a strip wetted with saline (single drop and flicked to remove excess). Testing will start about 1 minute after fluorescein application. An average of three times will be utilized. A stopwatch will be used for timing. * Total Corneal Fluorescein Staining (NEI scale): Sodium fluorescein from TBUT testing will be used to evaluate corneal fluorescein staining. After waiting for about 2-minute, corneal staining will be assessed with a cobalt blue light and a yellow filter. Corneal staining will be graded with the original National Eye Institute (NEI) grading scale; 0-3 score/region (5 regions) with 0-15 score/eye. Meibomian Gland Secretion Score (0-15 scale): The 5 central glands on lower eyelid will be evaluated by the investigator with their finger (each scored 0-3): 0 = normal; 1 = thick/yellow; whitish, particulate; 2 = paste; 3 = none/occluded. The investigator will do their best to grade the same 5 glands each visit

Phase 4
Waitlist Available

The Southern College of Optometry

Alcon Research

Image of U.C. Berkeley Clinical Research Center in Berkeley, United States.

Cooling Eyedrops for Dry Eye Syndrome

18+
All Sexes
Berkeley, CA

In dry eye (DE), either insufficient aqueous tears are produced or the tears evaporate off the ocular surface too quickly. Meibomian gland dysfunction (MGD) results in poor quality or insufficient meibum being expressed during blinking, leading to a thinner tear lipid layer and faster aqueous tear evaporation. MGD is a major factor in evaporative dry eye globally. Activation of TRPM8 receptors on the cornea and eyelid margins gives a cooling sensation, which may increase the basal production of both aqueous tears and meibum through parasympathetic neural circuitry. The investigators hypothesize that acoltremon (TRYPTYR) 0.003% eye drops can increase tear lipid layer thickness and reduce the tear thinning rate.

Phase 4
Waitlist Available

U.C. Berkeley Clinical Research Center

Alcon Research

Have you considered Miralax clinical trials?

We made a collection of clinical trials featuring Miralax, we think they might fit your search criteria.
Go to Trials
Image of The University of South Florida in Tampa, United States.

Acoltremon for Dry Eye Syndrome

18+
All Sexes
Tampa, FL

This study is designed to provide clinical data on how acoltremon ophthalmic solution 0.003% affects tear production and ocular symptoms in participants with tear deficiency and concurrent neuropathic corneal pain. Acoltremon is formulated to help increase natural tear production by activating TRPM8 (Transient Receptor Potential Melastatin 8) receptors on cold-sensitive corneal nerves. It is thought that this study treatment may help participants by increasing tear production while potentially reducing neuropathic ocular symptoms, including pain and discomfort. Participants will be followed for 8 weeks, evaluating the mean change in unanesthetized Schirmer test score between 3 minutes post-drop at Week 8 compared to pre-drop at baseline (Day 1), change in neuropathic symptom intensity as measured by a 0-10 VAS (Visual Analog Scale) from baseline to Week 8, and change in quality of life as assessed by the Ocular Pain Assessment Survey (OPAS) from baseline to Week 8. The study will also evaluate changes in corneal nerve structure, nerve function, corneal sensitivity, ocular surface symptoms, and treatment satisfaction.

Phase 4
Waitlist Available

The University of South Florida

Pedram Hamrah, MD

Alcon Research

Image of Kannarr Eye Care in Pittsburg, United States.

Lacrifill for Dry Eye Syndrome

18 - 80
All Sexes
Pittsburg, KS

Dry Eye Disease is defined as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.' 'By the The Tear Film and Ocular Surface Society. Despite there being a number of factors that impact DED however one factor that has been considered likely is that of a complication from ocular surgery itself. Which can cause both corneal nerve, and ocular surface damage. Therefore this study aims to determine how Lacrfill performs in preventing post-operative dry eye symptoms in those who have recently had unilateral cataract surgery.

Phase 4
Recruiting

Kannarr Eye Care (+1 Sites)

Have you considered Miralax clinical trials?

We made a collection of clinical trials featuring Miralax, we think they might fit your search criteria.
Go to Trials

Have you considered Miralax clinical trials?

We made a collection of clinical trials featuring Miralax, we think they might fit your search criteria.
Go to Trials